We here report an experimentally verified binding mode for the known tripeptidomimetic CXCR4 antagonist KRH-1636 (1). A limited SAR study was first conducted based on the three functionalities of 1, followed by site-directed mutagenesis studies. The receptor mapping showed that both the potency and affinity of 1 were dependent on the 
CXCR4 has emerged as a promising strategy for anti-HIV therapy. CXCR4 has also been shown to play an important role in angiogenesis, metastasis and stem-cell mobilization. 2, 4 Consequently, development of CXCR4 antagonists for therapeutic applications remains an important goal.
Significant advances in the development of novel CXCR4 antagonists have been made and several different classes of CXCR4 antagonists, both peptides and non-peptides, have been reported. [14] [15] [16] So far, the hematopoietic stem cell mobilizing agent plerixafor (AMD3100, Figure   1A ) 17 is the only CXCR4 antagonist that has reached the market. 18 Due to its high positive charge at physiological pH, AMD3100 exhibits poor oral bioavailability, and is therefore administered by subcutaneous injection.
Extensive studies by Fujii and co-workers on polyphemusin II-derived peptide CXCR4
antagonists culminated in the discovery of the potent cyclopentapeptide antagonist FC131
( Figure 1B) . 19 Successive SAR studies of FC131 have since shown that the Arg 1 -Arg 2 -2-Nal 3 tripeptide fragment of the cyclopentapeptide serves as an essential recognition motif for peptidebased CXCR4 antagonists, [20] [21] [22] [23] [24] providing impetus for development of tripeptidomimetic ligands that block CXCR4. Indeed, a series of tripeptide-like CXCR4 antagonists containing a central arginine residue has been reported by Kureha Chemical Industries [25] [26] [27] with the potent 
(AMD11070)
F E which resulted in the identification of plausible binding modes for the bicyclam AMD3100, [36] [37] [38] its monocyclam analogs, 39, 40 and the non-cyclam 4 (AMD11070, Figure 1F ). 40 However, while the molecular pharmacology of the prototype small-molecule peptide and non-peptide CXCR4
antagonists has been extensively characterized, experimental binding mode studies for the more drug-like tripeptidomimetic CXCR4 antagonists have not been reported. Thus, in order to facilitate rational design of novel peptidomimetic CXCR4 antagonists, we here report the binding mode of the known tripeptidomimetic CXCR4 antagonist 1 using a combination of SAR studies, receptor mapping by site-directed mutagenesis, and molecular docking.
RESULTS AND DISCUSSION
SAR Study. Design. The lead compound 1 was developed from a hit compound identified through screening of a chemical library, 28, 29 and although recent patent literature discloses compounds related to 1, [25] [26] [27] no SAR data has been reported for this compound class. In order to confirm the importance of the functionalities in 1 that could be assumed to represent pharmacophoric groups, we first carried out a limited SAR study focusing on the two positively charged groups (R 1 and R 2 ) and the aromatic group (R 3 ) (Figure 2 ). In order to probe the R 1 position, the pyridine ring was replaced with a phenyl ring (5), the pyridin-2-ylmethyl substituent was removed to give the primary amine (6) , and the charged (pyridin-2-ylmethyl)amino moiety was removed altogether (7) . The importance of the charged guanidino group (R 2 ) was investigated by replacing it with a urea group (8) , while the aromatic position (R 3 ) was probed by removal of the naphthalene unit (9). Chemistry. Compounds 1 and 5-9 ( Figure 2 ) were all prepared by adopting a procedure previously reported for the synthesis of 1 (Scheme 1). 29 For compound 1, the right-hand side was prepared by N-alkylation of Boc-protected pyridin-2-ylmethanamine (10) with methyl 4-(bromomethyl)benzoate followed by hydrolysis of the methyl ester to give carboxylic acid 11.
The left-hand side was assembled by coupling of Fmoc-L-Arg(Pbf)-OH with (S)-1-(naphthalen-1-yl)ethanamine using PyBOP as the coupling reagent, followed by Fmoc-deprotection with diethylamine in DMF to afford amine 12. Coupling of the two halves (11 and 12) was facilitated by EDCI/HOBt, and subsequent removal of the Boc and Pbf protecting groups by treatment with a TFA cocktail gave 1. For the preparation of 6 and 7, the left hand side (12) was coupled with N-Boc 4-(aminomethyl)benzoic acid and 4-methylbenzoic acid, respectively. Analog 5 was prepared by N-alkylation of 6 with benzyl bromide using K 2 CO 3 as base and DMF as solvent.
The R 2 analog 8 was prepared using Fmoc-protected citrulline as the starting material while the R 3 analog 9 was prepared by use of ethanamine in the first coupling step (Scheme 1). Similarly, the loss of potency for the R 3 analog 9 (EC 50 > 100 µM) confirms an important role for the naphthyl group. Earlier attempts to improve the pharmacokinetic profile of the bicyclam CXCR4 antagonists, i.e. AMD3100 ( Figure 1A ), led to the discovery of the monocyclam AMD3465 (Figure 3) , 41 which was shown to be 22-fold more potent than its precursor AMD3100 39 and contains the same (pyridin-2-ylmethyl)amino moiety as 1. The importance of this group for the antagonistic activity of AMD3465 has been investigated previously using the analogs 13 (AMD3529) and 14 (AMD3389) (Figure 3 ), 39 which are structural counterparts of the KRH-analogs 5 and 7 in the present study ( Figure 2 ). In line with the present findings for 5 and 7 ( Regarding the central Arg residue in 1 (R 2 ), it has been suggested that this position could correlate to Arg 2 in the cyclopentapeptide antagonist FC131 (Figure 1 ). 32 SAR studies of the cyclopentapeptides have shown that the Arg 2 position is very sensitive to modifications, 20, 23 and that replacement of the guanidino group with a urea group (Cit 2 ) leads to complete loss of antagonistic potency, 23 which is in agreement with the present data for the KRH-analog 8.
Collectively, the findings from this initial SAR study confirmed that the secondary amine, the guanidino group, and the aromatic naphthyl group are essential for the antagonistic potency of 1, while the pyridine ring in R 1 position contributes to increased potency. TM5. In most cases, the mutations included replacement with Ala; however, certain acidic Asp residues were alternatively substituted with the structurally similar and uncharged Asn residue.
Identification of Binding
Selective substitutions with Trp were also done in order to introduce more bulk. We have recently utilized the same receptor library to map the binding of the cyclopentapeptide CXCR4
antagonist FC131, where we reported the surface expression (using ELISA) and functional response to CXCL12 of WT-CXCR4 and all mutant receptors 35 (the same data is provided in Table 2 ). While there was some variation in surface expression and ability to be activated by CXCL12, the receptors in the mutant library were considered suitable for mapping of the binding site, as previously discussed.
35
Inhibition of CXCL12-induced Activation of CXCR4. We first assessed the antagonistic potency of 1 on the entire CXCR4 mutant library ( Table 2 ). The H113A, D262N, and H281A mutations were found to have the largest impact (>25-fold reduction) on the antagonistic potency of 1 relative to WT-CXCR4 (the position of residues based on the generic numbering system proposed by Baldwin 42 and modified by Schwartz 43 followed by the Ballesteros/Weinstein numbering system 44 is given in Tables 2 and 3 ). mutants led to increased potency (>2-fold).
As the mutagenesis data for 1 alone did not provide information about which parts of the ligand that interact with the different parts of the receptor, the R 1 analogs 5 and 6 ( Figure 2 ), which showed decent activity on WT-CXCR4 (Table 1) , were also included in the mutagenesis study to further probe the molecular interactions of the R 1 -side chain with CXCR4. The collective functional data analysis for 1, 5, and 6 (Table 2) showed that the mutations in TM1 (Y45A), TM2 (W94A, D97A), TM3 (H113A, T117A), TM4 (D171N), and ECL2 affected the three ligands in a similar manner. However, several mutations in TMs 5-7 affected the three ligands in a distinctive manner. Specifically, the H281A mutation in TM7 was the mutation with largest effect on the potency of 1 (61-fold reduction), but affected analog 5 to a much lesser extent (6-fold). Thus, the overall trend identified in the phosphatidylinositol (PI) turnover experiments for 1, 5, and 6 (Table 2) suggests that the structurally modified R 1 group contacts TMs 5-7; this trend is further illustrated in Figure 4 .
The absolute majority of the mutations had no or little effect on the potency of CXCL12 ( Table   2 ), demonstrating that most of the mutants were functional. However, the W94A, D97A, and D187A mutations reduced the agonistic potency of CXCL12 by 8-14 fold (Table 2) .
Furthermore, the Y116A and E288A mutants were not activated by CXCL12 in spite of expression levels of 69 and 77%, respectively (Table 2) ; consequently, no data on the antagonistic action of 1, 5, and 6 on these mutants are available. In line with the findings in the present study, the D97A, D187A, and E288A mutations have previously been found to affect both the binding and signaling of CXCL12. 37, [45] [46] [47] [48] [49] Moreover, Trp 94 and Tyr 116 , together with the three aforementioned residues, have been implicated as part of "site two" in the "two-site model"
for binding of CXCL12 to CXCR4. 33, 45, 50, 51 Additionally, the direct interaction of Tyr 116 with agonists has been suggested in activation of GPCRs. 34, 52 Thus, for these residues there are certain limitations in using CXCL12 as a probe. (functional assay).
a Data for CXCL12 activation are from ref. 35. b The position of each residue is given based on the generic numbering system proposed by Baldwin and modified by Schwartz, followed by the Ballesteros/Weinstein numbering system. c F mut is the ratio of the mutant and WT-CXCR4 potencies. Red: F mut >25; orange: F mut from 10-25; yellow: F mut from 5-10; green: F mut <0.5. EC 50 values >100 μM are underlined and also colored red. P<0.001***, P<0.01**, P<0.05*.
d The number of independent experiments is shown in parentheses (n).
e These mutant receptors were also tested in binding assay (Table 3 ). 
Displacement of Radiolabeled Monoclonal Antibody ( 125 I-12G5).
To address the issue of reduced activity of CXCL12 in certain mutants (W94A, D97A, Y116A, D187A, and E288A) a competitive binding assay using the radiolabeled monoclonal antibody 12G5 ( 125 I-12G5) was employed to probe ligand affinity (Table 3) . A good correlation between anti-HIV potency and binding affinity measured as displacement of 125 I-12G5 has previously been demonstrated for the bicyclam antagonists, 36, 38, 53 which represents an additional advantage of using 12G5 as radioligand. In addition to the five mutants mentioned above, the binding experiments were extended to also include four of the mutants that were identified as important for the potency of 1 in the functional assay (H113A, D171N, D262N, and H281A). All nine mutants had similar affinities for 12G5 as the WT receptor ( Table 3 ), meaning that the mutations did not significantly affect receptor folding. This finding clearly illustrates the differences between displacing 125 I-12G5 (Table 3) and inhibiting the action of CXCL12 (Tables 1 and 2 ). The two R 1 analogs 5 and 6 did not completely displace 12G5 ( Figure 5B ) -which also indicates an allosteric binding mode -and were therefore excluded from further binding experiments. The affinity of 1 determined against 125 I-12G5 was strongly (8-to >12-fold) negatively affected by the TM3 mutants H113A, the TM4 mutant D171N, the TM5 mutant D262N, and the TM7 mutants H281A and E288A ( To summarize, the functional studies (Tables 1 and 2 ) and the binding studies ( e The position of each residue is given based on the generic numbering system proposed by Baldwin and modified by Schwartz, followed by the Ballesteros/Weinstein numbering system.
Molecular Docking and Derived Binding Model. Binding Model: Key Interactions. In order
to rationalize the experimental data, 1 was docked to the X-ray structure of CXCR4 (PDB code 3OE0) 33 using Schrödinger's induced-fit docking protocol, 54 which models the conformational changes induced by ligand binding. In order to avoid generation of irrelevant poses, a H-bond constraint was set on His 113 (N δ1 ), which was shown to be highly important for both the affinity and potency of 1. Visual inspection of the 15 generated ligand-receptor complexes resulted in the identification of a pose that was in agreement with the experimental data. In our proposed binding model (Figure 6 ), the (pyridin-2-ylmethyl)amino moiety (R 1 side chain) of 1 is oriented towards the TM6 and TM7 region, and the R 1 side chain adopts a bent conformation around the Figure S1 ) implies that the Y116A mutation can affect the overall geometry of the main binding crevice, specifically the orientations of TM3 and TM7.
Thus, the Y116A mutation may indirectly affect the potential interactions between the ligand and The model further shows an interaction between the guanidino group of Arg 188 and the ligand backbone ( Figure 6 ), which was also previously identified in the binding modes of the peptide antagonists FC131 and 2. 23, 33, 58 However, the R188A mutation did not have any effect on the antagonistic potency of 1 or the two analogs (Table 2) ; interestingly, the R188A-mutant was also reported to have no effect on the potency of FC131. 35 A possible explanation is that both 1 and FC131 are doubly positively charged, which results in electrostatic repulsion by Arg 188 .
Substitution of Arg 188 with Ala (R188A) therefore results in two opposing effects: an unfavorable removal of the H-bond interaction with the ligand, and a favorable removal of the electrostatic repulsion. Thus, it can be hypothesized that the net result is no overall effect of the R188A mutation on 1 and FC131. While the effect of most mutations (Tables 2 and 3) can be explained by the binding model, it
is not possible to rationalize every single one. For example, the W94A and D97A mutations both led to increased potencies for all three analogs (Table 2) . Earlier studies have suggested the involvement of these residues in the second binding step ("site two") for the endogenous ligand CXCL12, 33, 45 and the present mutagenesis data showed a reduced ability (13-14 fold) of CXCL12 to induce signaling for the W94A and D97A mutants. Moreover, the X-ray structure of Table 2 . Second, the potential pre-interaction with Asp 97 is removed in the D97A mutant, which allows easier access of the ligands to the TM binding pocket. Third, the involvement of the Trp 94 in the hydrophobic pocket surrounding the naphthalene ring (R 3 -position) in 1 ( Figure   6 ), suggests that removal of the bulky side chain of Trp (W94A-mutant) allows a more energetically favorable position of the naphthyl group in the binding pocket.
Conversely, mutation of hydrophobic residues in TM6 and TM7 reduced the potency of 1 (W252A, I259A and I284A) and 6 (W252A and I284A Consequently, the binding mode of 3 differs from other reported binding modes of CXCR4
antagonists (see below), and is distinct from the present binding mode for 1.
Peptide Antagonists. Prior to the publication of the X-ray structure of CXCR4, computational binding mode studies had been performed for the cyclopentapeptide CXCR4 antagonist FC131 62, 63 and 1 63 based on molecular docking to homology models of CXCR4 that were built on the crystal structure of bovine rhodopsin. These studies were purely theoretical, i.e. not based on any experimentally verified ligand-receptor interactions. Moreover, when the X-ray structure of CXCR4 33 was revealed in 2010 it showed that bovine rhodopsin was a poor template for Figure 6 ); structural comparison of the reported binding mode for FC131 35 and the present binding mode for 1 (Supporting Information, Figure S2 and 1 inhibit binding of the same set of monoclonal antibodies, directed against the extracellular loops of CXCR4, it has been suggested that they have similar binding sites and molecular mode of action. 28, 65 As Asp 171 , Asp 262 , and indirectly Glu 288 are also involved in binding of 1 (Figure 6 ), the present study confirms that these two compounds bind to the same receptor region.
In addition to the key interactions seen for AMD3100, the monocyclam analog AMD3465
( Figure 3) The interaction pattern for the non-cyclam 4 ( Figure 1F ) is more unclear, but it has been suggested that it binds in a similar fashion as AMD3100 and AMD3465; however, Asp 97 and Asp 171 appeared to have a unique importance for the binding of this analog.
40, 66

CONCLUSIONS
The present study describes the binding of the prototype tripeptidomimetic antagonist 1 to column (250 mm × 19 mm, 10 µm particle size) using 15 mL/min flow rate or a Waters 2695 system equipped with an XBridge™ C 18 column (250 mm × 10 mm, 5 µm particle size) using 10 mL/min flow rate with mixtures of acetonitrile and water (both containing 0.1% TFA) as the eluent in both cases Analytical RP-HPLC was performed on a Waters 2695 system equipped with an XBridge™ C 18 column (250 mm × 4.6 mm, 5 µm particle size,) using 1 mL/min flow rate with detection at 214 nm and 254 nm facilitated by a PDA detector (210 -310 nm). In some cases, analyses were performed on a Waters ACQUITY UHPLC H-Class equipped with a Waters ACQUITY UHPLC BEH C 18 column (1 × 150 mm, 1.75 µm particle size) with a 0.120 mL/min flow rate. All compounds undergoing biological evaluation were found to be of >95% purity as judged by analytical RP-HPLC with PDA detection (210 -310 nm). -2-ylmethyl) 552.3081. The purity of the title compound was found to be >99% using analytical RP-HPLC (diode array detection, 210 nm -310 nm). 461.2660, found 461.2664. The purity of the title compound was found to be >99% using analytical RP-HPLC (diode array detection, 210 nm -310 nm). 5-guanidino-1-(((S)-1-(naphthalen-1-yl) was added. To this suspension, benzyl bromide (10 µL, 0.09 mmol) was added slowly, and the reaction mixture was allowed to stir at rt for 24 h. Water (1 mL) was added and the mixture was extracted with diethyl ether (10 mL), washed with water (2 x 5 mL) and a saturated solution of NaCl (10 mL). The organic layer was dried over anhydrous MgSO 4 , filtered and the solvents were removed under reduced pressure. The crude product was purified using RP-HPLC followed by lyophilization to give the title compound as a fluffy white material. 1 found 551.3131. The purity of the title compound was found to be >99% using analytical RP-HPLC (diode array detection, 210 nm -310 nm). Statistical Calculations. The apparent EC 50 and IC 50 values were determined by nonlinear regression using the GraphPad Prism 4 software (GraphPad Software, San Diego, CA). P-values were calculated using unpaired two-tailed t-test with 95% confidence intervals. The data analysis was performed as recently described.
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Computational Modeling Procedure. All molecular modeling calculations were performed using the Schrödinger software suite 2012. 70 Default settings were used, if not specified otherwise. The crystal structure of CXCR4 in complex with 2 (PDB-code: 3OE0) 33 was first prepared and optimized with the Protein Preparation Wizard workflow 71 using the same procedure as previously described. 23 The automatically assigned tautomeric and protonation states (pH 7.4) for ionizable residues were kept, except for Asp 262 , which was manually assigned a negative charge (predicted to be neutral). The ligand (1) was docked to the prepared receptor structure using the induced-fit workflow 54 with a docking box of (26 Å) 3 centered on Asp 187 . The ligand was built with two positive charges (the guanidino group and the amino group), and the "penalize nonplanar conformation" option was chosen for amide bonds.
In the first step (Glide docking: flexible ligand, rigid receptor), 50 poses were generated using a softened van der Waals potential (scaling 0.5) for both receptor and ligand. In the second step kcal/mol were kept. In the absence of constraints, a number of irrelevant poses were generated, and a H-bond constraint (applied in both docking steps) was therefore assigned to the N δ1 atom of His 113 , which resulted in the identification of the binding mode for 1 that is shown in Figure 6 . 
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